Mizuho raised the firm’s price target on Harmony Biosciences (HRMY) to $44 from $42 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q4 report. Harmony’s lead asset Wakix making steady progress towards becoming a blockbuster product. the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Earnings Call Highlights Growth and Challenges
- Harmony Biosciences price target lowered to $70 from $75 at H.C. Wainwright
- Harmony Biosciences price target raised to $33 from $31 at BofA
- Cautious Outlook: Sell Rating for Harmony Biosciences Due to Pipeline Concerns and Generic Competition Risks
- Harmony Biosciences Reports Strong 2024 Financial Results